Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion
Copyright © 2021. Published by Elsevier Ltd..
Non-small cell lung cancer (NSCLC) patients with oncogenic ROS1 rearrangements would inevitably develop drug resistance and disease progression after receiving targeted oncogene therapy. Here, we present a metastatic lung adenocarcinoma patient harboring a CD74-ROS1 fusion who initially responded to crizotinib and then developed resistance after acquiring a rarely reported BRAF V600E mutation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Cancer treatment and research communications - 27(2021) vom: 15., Seite 100377 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ren, Shuang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.12.2021 Date Revised 30.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ctarc.2021.100377 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324988818 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324988818 | ||
| 003 | DE-627 | ||
| 005 | 20231225191500.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctarc.2021.100377 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM324988818 | ||
| 035 | |a (NLM)33945921 | ||
| 035 | |a (PII)S2468-2942(21)00075-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ren, Shuang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.12.2021 | ||
| 500 | |a Date Revised 30.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
| 520 | |a Non-small cell lung cancer (NSCLC) patients with oncogenic ROS1 rearrangements would inevitably develop drug resistance and disease progression after receiving targeted oncogene therapy. Here, we present a metastatic lung adenocarcinoma patient harboring a CD74-ROS1 fusion who initially responded to crizotinib and then developed resistance after acquiring a rarely reported BRAF V600E mutation | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BRAF | |
| 650 | 4 | |a Crizotinib | |
| 650 | 4 | |a ROS1 | |
| 650 | 4 | |a Resistance | |
| 650 | 7 | |a Antigens, Differentiation, B-Lymphocyte |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Histocompatibility Antigens Class II |2 NLM | |
| 650 | 7 | |a Oncogene Proteins, Fusion |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a invariant chain |2 NLM | |
| 650 | 7 | |a Crizotinib |2 NLM | |
| 650 | 7 | |a 53AH36668S |2 NLM | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ROS1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a BRAF protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Huang, Sisi |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Xinqing |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Luhuai |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Chaonan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a He, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Junwei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Bixun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer treatment and research communications |d 2016 |g 27(2021) vom: 15., Seite 100377 |w (DE-627)NLM272607894 |x 2468-2942 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g day:15 |g pages:100377 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ctarc.2021.100377 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |b 15 |h 100377 | ||